new BindingDB logo
myBDB logout

BDBM50101765 (2S)-2-{[(benzyloxy)carbonyl]amino}-3-[(5-{2-[(1,4,5,6-tetrahydropyrimidin-2-yl)carbamoyl]ethyl}thiophen-2-yl)formamido]propanoic acid::CHEMBL304217

SMILES: OC(=O)[C@H](CNC(=O)c1ccc(CCC(=O)NC2=NCCCN2)s1)NC(=O)OCc1ccccc1

InChI Key: InChIKey=LUSHAVDQHKTOOU-KRWDZBQOSA-N

Data: 3 IC50

Find this compound or compounds like it in BindingDB or PDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 3 hits for monomerid = 50101765   
Target/Host
(Institution)
LigandTarget/Host
Links
Ligand
Links
Trg + Lig
Links
Ki
nM
ΔG°
kcal/mole
IC50
nM
Kd
nM
EC50/IC50
nM
koff
s-1
kon
M-1s-1
pHTemp
°C
ITGAV/ITGB3


(Homo sapiens (Human))
BDBM50101765
PNG
((2S)-2-{[(benzyloxy)carbonyl]amino}-3-[(5-{2-[(1,4...)
Show SMILES OC(=O)[C@H](CNC(=O)c1ccc(CCC(=O)NC2=NCCCN2)s1)NC(=O)OCc1ccccc1 |t:17|
Show InChI InChI=1S/C23H27N5O6S/c29-19(28-22-24-11-4-12-25-22)10-8-16-7-9-18(35-16)20(30)26-13-17(21(31)32)27-23(33)34-14-15-5-2-1-3-6-15/h1-3,5-7,9,17H,4,8,10-14H2,(H,26,30)(H,27,33)(H,31,32)(H2,24,25,28,29)/t17-/m0/s1
PDB

UniProtKB/SwissProt

antibodypedia
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem

Patents

PubMed
n/an/a 63n/an/an/an/an/an/a



Aventis Pharma Deutschland GmbH

Curated by ChEMBL


Assay Description
Concentration required to reduce binding of fibrinogen (Fg) to alpha IIb beta3 integrin by 50%


Bioorg Med Chem Lett 11: 2011-5 (2001)


BindingDB Entry DOI: 10.7270/Q2N87930
More data for this
Ligand-Target Pair
Integrin alpha-IIb/beta-3


(Homo sapiens (Human))
BDBM50101765
PNG
((2S)-2-{[(benzyloxy)carbonyl]amino}-3-[(5-{2-[(1,4...)
Show SMILES OC(=O)[C@H](CNC(=O)c1ccc(CCC(=O)NC2=NCCCN2)s1)NC(=O)OCc1ccccc1 |t:17|
Show InChI InChI=1S/C23H27N5O6S/c29-19(28-22-24-11-4-12-25-22)10-8-16-7-9-18(35-16)20(30)26-13-17(21(31)32)27-23(33)34-14-15-5-2-1-3-6-15/h1-3,5-7,9,17H,4,8,10-14H2,(H,26,30)(H,27,33)(H,31,32)(H2,24,25,28,29)/t17-/m0/s1
PDB

KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem

Patents

PubMed
n/an/a 4.50E+3n/an/an/an/an/an/a



Aventis Pharma Deutschland GmbH

Curated by ChEMBL


Assay Description
Concentration required to reduce binding of fibrinogen (Fg) to alpha IIb beta3 integrin by 50%


Bioorg Med Chem Lett 11: 2011-5 (2001)


BindingDB Entry DOI: 10.7270/Q2N87930
More data for this
Ligand-Target Pair
ITGAV/ITGB3


(Homo sapiens (Human))
BDBM50101765
PNG
((2S)-2-{[(benzyloxy)carbonyl]amino}-3-[(5-{2-[(1,4...)
Show SMILES OC(=O)[C@H](CNC(=O)c1ccc(CCC(=O)NC2=NCCCN2)s1)NC(=O)OCc1ccccc1 |t:17|
Show InChI InChI=1S/C23H27N5O6S/c29-19(28-22-24-11-4-12-25-22)10-8-16-7-9-18(35-16)20(30)26-13-17(21(31)32)27-23(33)34-14-15-5-2-1-3-6-15/h1-3,5-7,9,17H,4,8,10-14H2,(H,26,30)(H,27,33)(H,31,32)(H2,24,25,28,29)/t17-/m0/s1
PDB

UniProtKB/SwissProt

antibodypedia
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem

Patents

PubMed
n/an/a 7n/an/an/an/an/an/a



Aventis Pharma Deutschland GmbH

Curated by ChEMBL


Assay Description
Concentration required to reduce binding of Kistrin to Vitronectin receptor (alpha V beta 3) by 50%


Bioorg Med Chem Lett 11: 2011-5 (2001)


BindingDB Entry DOI: 10.7270/Q2N87930
More data for this
Ligand-Target Pair